Ipilimumab/nivolumabDermatitis, diarrhoea and hepatitis: case report

被引：0

|

作者：

机构：

来源：

Reactions Weekly | 2019年 / 1753卷 / 1期

关键词：

D O I：

10.1007/s40278-019-62094-1

中图分类号：

学科分类号：

摘要：

引用

收藏

页码：202 / 202

相关论文

共 50 条

[21] Ipilimumab/prednisoneAutoimmune colitis and cytomegalovirus hepatitis: case report
[J]. Reactions Weekly, 2015, 1557 (1) : 131 - 131
[22] Ipilimumab/nivolumabAutoimmune hepatitis and autoimmune thyroiditis: case report
[J]. Reactions Weekly, 2017, 1665 (1) : 162 - 162
[23] Ipilimumab/nivolumabImmune-related hepatitis: case report
[J]. Reactions Weekly, 2020, 1792 (1) : 134 - 134
[24] Ipilimumab/nivolumabGrade 3 autoimmune hepatitis: case report
[J]. Reactions Weekly, 2022, 1929 (1) : 359 - 359
[25] Ipilimumab/pembrolizumabAutoimmune hepatitis and adrenal crisis: case report
[J]. Reactions Weekly, 2018, 1687 (1) : 124 - 124
[26] Ipilimumab/nivolumabThrombocytopenia, neutropenia and autoimmune hepatitis: case report
[J]. Reactions Weekly, 2018, 1725 (1) : 184 - 184
[27] Ipilimumab/nivolumab/pembrolizumabLack of efficacy, hepatitis and hepatitis relapse: case report
[J]. Reactions Weekly, 2023, 1975 (1) : 200 - 200
[28] Infliximab/ipilimumab/methylprednisoloneAcneiform skin rash, diarrhoea and lack of efficacy: case report
[J]. Reactions Weekly, 2022, 1907 (1) : 257 - 257
[29] Ipilimumab/NivolumabImmune checkpoint inhibitor-related diarrhoea and colitis: case report
[J]. Reactions Weekly, 2020, 1818 (1) : 153 - 153
[30] Ipilimumab/nivolumabColitis and diarrhoea: 11 case reports
[J]. Reactions Weekly, 2020, 1810 (1) : 120 - 120

← 1 2 3 4 5 →